What happened with VVOS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Vivos Therapeutics serves people with obstructive sleep apnea, a condition in which breathing repeatedly stops during sleep. Its Vivos Method combines customized C.A.R.E. oral appliances, worn mainly in the evening and overnight, with treatment protocols delivered by trained providers. Its supported sleep practices also offer other treatments, including CPAP machines that keep the airway open with pressurized air.
The company has shifted away from recruiting and training dentists toward acquiring or partnering with sleep practices, including Sleep Center of Nevada (SCN). Services now bring in more revenue than product sales. Patients and their insurers pay for testing and treatment; Vivos receives management-services fees and revenue from products and services offered through supported practices. It also sells appliances to independent trained dentists, who bill their own patients separately. Patients generally pay for the Vivos Method out of pocket, with insurance reimbursement where available.
The newer practice-based model still has limited operating history. Revenue depends on recruiting trained clinicians, their adoption of Vivos treatments, and insurance credentialing and coverage. Laws restricting corporate medical practice shape its management arrangements: licensed providers retain independent clinical judgment. Vivos may promote its appliances only for their FDA-cleared uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ResMed competes for the obstructive sleep apnea patients who could pay for Vivos Therapeutics’ customized oral appliances, selling healthcare providers and patients systems that push air through a mask to keep the airway open during sleep, known as CPAP. Its device and mask sales are the competing treatment business to watch, rather than its residential-care software revenue.
Inspire Medical Systems competes with Vivos Therapeutics’ patient-paid oral appliances for moderate to severe obstructive sleep apnea treatment, selling hospitals and surgery centers implants that stimulate a nerve to move the tongue forward and keep the airway open. Watch insurance coverage and reimbursement for Inspire’s implants: U.S. hospitals and surgery centers bill insurers and Medicare for treatment, unlike Vivos’s consumer-priced appliance course.
ResMed Inc. earningsRMD
ResMed’s report will show demand for its CPAP machines and masks, giving Vivos Therapeutics a read on demand for a competing sleep-apnea treatment.
Focus on ResMed’s device and mask sales, not its residential-care software. Stronger sales would show continued demand for CPAP, which uses airflow to keep the airway open, and continued competition for Vivos’s oral appliances. Weaker sales would suggest demand for that competing treatment may be easing, but ResMed’s report alone cannot explain why or show that patients are switching to Vivos.
Vivos Therapeutics, Inc. earningsThis company
Vivos Therapeutics’ report will show whether sleep testing and treatment at its SCN centers can offset weaker sales of its oral appliances.
Read service revenue beside product revenue, noting how much services come from sleep testing and patient treatment and how appliance and tooth-positioner sales are doing. Rising service revenue with stable product revenue would show the sleep-center business is expanding rather than just replacing the old one; rising services with continued product declines would show the new channel is carrying revenue as the legacy channel shrinks.
